Biotech News

Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

Xeris Pharmaceuticals (XERS)Xeris Pharmaceuticals2026-06-25 13:46 ESTEarnings

Total product revenue increased 40% YoY to $74 million Recorlev® revenue grew 109% YoY to $37 million Updating full-year 2025 total revenue guidance to $285-$290 million ; previously $280-$290 million Hosts conference call and webcast today at 8:30 a.m. ET CHICAGO --(BUSINESS WIRE)--Nov.

Open original release

Related news

XERSXeris Pharmaceuticals2026-06-25 13:46 EST

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®

XERSXeris Pharmaceuticals2026-06-25 13:46 EST

Xeris Biopharma Announces Private Exchange of Convertible Notes

XERSXeris Pharmaceuticals2026-06-25 13:46 EST

Xeris Biopharma Reports First Quarter 2026 Financial Results

XERSXeris Pharmaceuticals2026-06-25 13:46 EST

Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025

XERSXeris Pharmaceuticals2026-06-25 13:46 EST

Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application

XERSXeris Pharmaceuticals2026-06-25 13:46 EST

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

XERSXeris Pharmaceuticals2026-06-25 13:46 EST

Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue

XERSXeris Pharmaceuticals2026-06-25 13:46 EST

Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

XERSXeris Pharmaceuticals2026-06-25 13:46 EST

Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

XERSXeris Pharmaceuticals2026-06-25 13:46 EST

Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

View all latest news

Xeris Pharmaceuticals

Xeris Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

XERSXeris Pharmaceuticals2026-06-26 12:18 EST

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®

XERSXeris Pharmaceuticals2026-06-26 12:18 EST

Xeris Biopharma Announces Private Exchange of Convertible Notes

XERSXeris Pharmaceuticals2026-06-26 12:18 EST

Xeris Biopharma Reports First Quarter 2026 Financial Results

XERSXeris Pharmaceuticals2026-06-26 12:18 EST

Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025

XERSXeris Pharmaceuticals2026-06-26 12:18 EST

Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States